Janney Montgomery Scott LLC Buys 137,133 Shares of BioCryst Pharmaceuticals, Inc. $BCRX

Janney Montgomery Scott LLC grew its stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 524.8% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 163,266 shares of the biotechnology company’s stock after acquiring an additional 137,133 shares during the quarter. Janney Montgomery Scott LLC’s holdings in BioCryst Pharmaceuticals were worth $1,554,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of BCRX. Larson Financial Group LLC boosted its stake in BioCryst Pharmaceuticals by 1,188.0% in the 4th quarter. Larson Financial Group LLC now owns 3,542 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 3,267 shares in the last quarter. Focus Partners Wealth bought a new stake in BioCryst Pharmaceuticals during the 3rd quarter valued at about $77,000. Mirae Asset Global Investments Co. Ltd. raised its holdings in BioCryst Pharmaceuticals by 26.1% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,231 shares of the biotechnology company’s stock worth $80,000 after buying an additional 2,115 shares during the last quarter. Envestnet Portfolio Solutions Inc. bought a new position in shares of BioCryst Pharmaceuticals in the fourth quarter worth approximately $81,000. Finally, Mercer Global Advisors Inc. ADV bought a new position in shares of BioCryst Pharmaceuticals in the third quarter worth approximately $81,000. Hedge funds and other institutional investors own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Stock Performance

BCRX stock opened at $10.45 on Friday. The company has a market cap of $2.66 billion, a price-to-earnings ratio of -5.87 and a beta of 0.55. The business’s 50-day moving average is $9.14 and its two-hundred day moving average is $8.44. BioCryst Pharmaceuticals, Inc. has a fifty-two week low of $6.00 and a fifty-two week high of $11.22.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported ($2.98) EPS for the quarter, missing the consensus estimate of $0.06 by ($3.04). The business had revenue of $156.41 million for the quarter, compared to analysts’ expectations of $151.12 million. BioCryst Pharmaceuticals had a negative net margin of 51.71% and a negative return on equity of 76.36%. BioCryst Pharmaceuticals’s revenue for the quarter was up 7.5% compared to the same quarter last year. During the same period in the previous year, the company earned $0.20 EPS. Equities analysts predict that BioCryst Pharmaceuticals, Inc. will post -2.61 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the stock. HC Wainwright reissued a “buy” rating and set a $32.00 price target on shares of BioCryst Pharmaceuticals in a research report on Tuesday, June 30th. Citizens Jmp increased their target price on BioCryst Pharmaceuticals from $25.00 to $28.00 and gave the company a “market outperform” rating in a research note on Thursday, May 7th. Wedbush lowered their price target on BioCryst Pharmaceuticals from $22.00 to $21.00 and set an “outperform” rating on the stock in a report on Thursday, May 7th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of BioCryst Pharmaceuticals in a research report on Monday, June 1st. Finally, Needham & Company LLC reduced their price objective on BioCryst Pharmaceuticals from $18.00 to $16.00 and set a “buy” rating for the company in a report on Wednesday, May 6th. Eight equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $21.78.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.